THURSDAY, Dec. 12, 2024 (HealthDay News) -- The Advisory Committee on Immunization Practices (ACIP) recommendations have been updated for the meningococcal serogroup B MenB-4C vaccine (Bexsero ...

GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

The vaccine that will be offered on the NHS is actually an existing childhood vaccine called 4CMenB (also sold under the brand name Bexsero). This vaccine is used to protect against meningococcal ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya.

The vaccine that will be offered on the NHS is actually an existing childhood vaccine called 4CMenB (also sold under the brand name Bexsero). This vaccine is used to protect against meningococcal ...

The vaccine, known as 4CMenB and sold by GSK as Bexsero, was not originally created with gonorrhoea in mind. It’s been authorised for more than a decade in both the UK and the European Union to ...

The meningococcal vaccine protects against diseases caused by certain types of bacteria . Learn who is at risk and CDC recommendations. Skip to content. Menu. Health A-Z ... Novartis Bexsero® vaccine ...

Since the rollout of the conjugate MenC vaccine in 2001 and the MenACWY in 2018, rates of invasive meningococcal disease have ...

Two Tasmanian women have been hospitalized with invasive meningococcal disease, bringing the number of cases nationally so ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group.

The FDA has approved MenQuadfi as the first-ever meningococcal vaccine for babies as young as 6 weeks old. It protects against invasive meningococcal disease (IMD) caused by meningococcal bacteria ...